Iveric Bio Stock Fundamentals
ISEEDelisted Stock | USD 39.95 0.00 0.00% |
IVERIC Bio fundamentals help investors to digest information that contributes to IVERIC Bio's financial success or failures. It also enables traders to predict the movement of IVERIC Stock. The fundamental analysis module provides a way to measure IVERIC Bio's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to IVERIC Bio stock.
IVERIC |
IVERIC Bio Company Current Valuation Analysis
IVERIC Bio's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current IVERIC Bio Current Valuation | 4.98 B |
Most of IVERIC Bio's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, IVERIC Bio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
CompetitionIn accordance with the recently published financial statements, IVERIC Bio has a Current Valuation of 4.98 B. This is 65.32% lower than that of the Biotechnology sector and 7.24% higher than that of the Health Care industry. The current valuation for all United States stocks is 70.03% higher than that of the company.
IVERIC Bio Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining IVERIC Bio's current stock value. Our valuation model uses many indicators to compare IVERIC Bio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across IVERIC Bio competition to find correlations between indicators driving IVERIC Bio's intrinsic value. More Info.IVERIC Bio is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all technique that is used if you cannot value IVERIC Bio by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.IVERIC Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses IVERIC Bio's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of IVERIC Bio could also be used in its relative valuation, which is a method of valuing IVERIC Bio by comparing valuation metrics of similar companies.IVERIC Bio is currently under evaluation in current valuation category among its peers.
IVERIC Fundamentals
Return On Equity | -0.55 | |||
Return On Asset | -0.3 | |||
Current Valuation | 4.98 B | |||
Shares Outstanding | 137.98 M | |||
Shares Owned By Insiders | 0.65 % | |||
Shares Owned By Institutions | 99.35 % | |||
Number Of Shares Shorted | 16.64 M | |||
Price To Earning | 4.17 X | |||
Price To Book | 3.81 X | |||
Gross Profit | (117.01 M) | |||
EBITDA | (192.28 M) | |||
Net Income | (185.21 M) | |||
Cash And Equivalents | 311.96 M | |||
Cash Per Share | 2.64 X | |||
Total Debt | 97.77 M | |||
Debt To Equity | 0.01 % | |||
Current Ratio | 11.98 X | |||
Book Value Per Share | 3.48 X | |||
Cash Flow From Operations | (163.77 M) | |||
Short Ratio | 5.25 X | |||
Earnings Per Share | (1.82) X | |||
Target Price | 39.1 | |||
Number Of Employees | 163 | |||
Beta | 1.1 | |||
Market Capitalization | 5.51 B | |||
Total Asset | 666.82 M | |||
Retained Earnings | (864.81 M) | |||
Working Capital | 627.24 M | |||
Current Asset | 121.07 M | |||
Current Liabilities | 14.54 M | |||
Z Score | 32.19 | |||
Net Asset | 666.82 M |
About IVERIC Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze IVERIC Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of IVERIC Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of IVERIC Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases . The company was incorporated in 2007 and is based in Parsippany, New Jersey. Iveric Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 133 people.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Other Consideration for investing in IVERIC Stock
If you are still planning to invest in IVERIC Bio check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the IVERIC Bio's history and understand the potential risks before investing.
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets |